V-Go indicated for use in adult patients requiring insulin.
†A U-100 fast- acting insulin should be used with V-Go. Humalog® (insulin lispro [rDNA origin] injection) and NovoLog® (insulin aspart [rDNA origin] injection) have been tested and found to be safe for use in V-Go.
Humalog® is a registered trademark of Eli Lilly and Company.
NovoLog® is a registered trademark of Novo Nordisk A/S.
Hear a Nurse Practitioner talk about how V-Go can help overcome the burdens of adherence to multiple daily injections, resulting in an increase in morale for her patients and better compliance.
References: 1. Lajara R, Fetchick DA, Morris DA, Nikkel C. Use of V-Go® insulin delivery device with sub-optimally controlled diabetes mellitus: a retrospective analysis from a large specialized diabetes system. Diabetes Ther. 2015;6(4):531-545. 2. Instructions for Patient Use. P/N 2614-00 Rev. A 05/2019. 3. Lajara R, Davidson JA, Nikkel C, Morris TL. Clinical and cost effectiveness of insulin delivery with V-Go disposable insulin delivery device versus multiple daily injections in patients with type 2 diabetes inadequately controlled on basal insulin. Endocrine Practice 2016 June;22(6):726-735. 4. Grunberger G, Rosenfeld CR, Bode BW, Abbott SD, Nikkel C, Shi L, Strange P. Effectiveness of V-Go for Patients with Type 2 Diabetes in a Real-World Setting: A Prospective Observational Study. Drugs Real World Outcomes. 2020 Mar;7(1):31-40. 5. Sutton D, Higdon C, Nikkel C, Hilsinger K. Clinical benefits over time associated with use of V-Go Wearable Insulin Delivery Device in adult patients with diabetes: a retrospective analysis. Advances in Therapy 2018 May; 35(5): 631-43. 6. Rosenfeld CR, Bohannon NJ, Bode B, et al. Endocrine Practice. 2012;18(5):660-667.